Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report

BACKGROUND: Everolimus, an inhibitor of the mammalian target of rapamycin, shows promising antitumor activity when combined with trastuzumab and chemotherapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer or when combined with endocrine agents for hormone receptor (HR)-po...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Bing, Ding, Lijuan, Wu, Shikai, Meng, Xiangying, Song, Santai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936809/
https://www.ncbi.nlm.nih.gov/pubmed/27445490
http://dx.doi.org/10.2147/OTT.S104398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936809/
https://www.ncbi.nlm.nih.gov/pubmed/27445490
http://dx.doi.org/10.2147/OTT.S104398

Ejemplares similares